FUNDAMENTAL AND CLINICAL STUDIES ON SULBACTAM/CEFOPERAZONE IN THE TREATMENT OF SURGICAL INFECTIONS

Abstract

A combination drug of sulbactam/cefoperazone (a ratio of 1: 1) was administered to 13 patients with surgical infections and 11 patients after gastrectomy. 1-2g of sublactam/cefoperazone diluted in 100ml of physiological saline was infused intravenously in 30 minutes, once or twice daily for 4-16 days. Total doses per patient ranged from 8 to 64g.
Clinical response in 13 surgical infecitions were: good in 6, fair in 2 and poor in 5 patients. No post operative infections were observed in the eleven patients who were administered the drug after gastrectomy.
Sulbactam and cefoperazone concentrations in peritoneal exudate after gastrectomy were measured in 10 patients, 3 patients given 2g/day and 7 patients 4g of sulbactam/cefoperazone. Sulbactam concentrations in exudate were on the average 2.3/4/ml on the 1st day, 2.9μg/ml on the 2nd day and 2.6 μg/ml on the 3rd day in the 2g administration group, whereas they were 6.1 μg/ml on the 1st, 4.4μg/ml on the 2nd and 4.6 μg/ml on the 3rd day in the 4g administration group.
Cefoperazone concentrations in exudate were about 4μg/ml by 2g and 12-15μg/ml by 4g administration of sulbactam/cefoperazone. Considering the good excretion into peritoneal exudate and excellent antibacterial activity of sulbactam/cefoperazone, this drug could be expected to inhibit bacterial growth in peritoneal exudate.
A systemic skin eruption appeared in a patient on the 15th day of prophylactic use, which was considered to be related to the drug. Four days after the discontinuation of the drug, the eruption disappeared. No other adverse reactions nor abnormal laboratory findings related to the use of the drug were observed.